Click Therapeutics – a leader in Digital Therapeutics as prescription medical treatments – recently announced that it has closed on a $20 million term loan from HSBC Innovation Banking, a division of HSBC Bank USA, N.A. And the term loan was partially drawn at closing, with the proceeds used to retire Click’s previous term loan. The undrawn balance remains fully available to help advance Click’s prescription digital therapeutic pipeline.
Click Therapeutics also recently announced four major co-development and commercialization collaborations to date for the treatment of major depressive disorder (MDD), schizophrenia, and substance use disorders. And Click is also progressing its lead internal program for the preventive treatment of migraine with pivotal data expected in 2024.
KEY QUOTES:
“The last few years have been a period of tremendous growth for Click, and we could not be more excited to partner with HSBC Innovation Banking, a leader in the innovation economy. We are pleased with the financial terms, which we believe reflect Click’s leadership in the industry and the progress we have made towards profitability. This capital will help us continue to fund important investments in our platform and pipeline.”
— Randall Stanicky, Chief Financial Officer of Click Therapeutics
“This is an exciting opportunity for HSBC Innovation Banking to partner with a truly innovative company in the digital therapeutic space. As Randall and his team look to grow their business, HSBC’s innovation network, combined with our size, strength, and international footprint, creates endless opportunity for Click at every phase of its growth.”
— Clark Hayes, Head of Business Development, Healthcare and Life Sciences for HSBC Innovation Banking
